TMS 2026: Menopause hormone therapy was associated with greater weight loss on semaglutide, but not sustained additional benefits with tirzepatide, in a new study.
Commentary|Videos|December 19, 2023
Key Developments in Obesity Medicine in 2023: An Expert Discussion
Author(s)Sydney Jennings
Angela Fitch, MD, president of the Obesity Medicine Association discusses key pharmaceutical and research developments in obesity medicine in 2023.
Advertisement
"What are the most important pharmaceutical and/or research developments in weight management and obesity medicine in 2023?"
Was a question Patient Care Online asked Angela Fitch, MD, president of the Obesity Medicine Association, in a recent interview. In the video below, Dr Fitch discusses advancements in the nutrient-stimulated hormone category of drug therapy for obesity; the release of
Dr Fitch is also the founder and chief medical officer at knownwell and the former co-director of the Massachusetts General Hospital Weight Center and faculty at Harvard Medical School.
Advertisement
Related to this article
EASD 2026: Oral semaglutide users lost 4.1% of body weight 3 months after switching from injections in an observational study without a comparator group.
EASD 2026: The combination of semaglutide/cagrilintide altered food-cue responses and showed a 22.4% estimated weight difference vs placebo; separate data found less organ fat in type 2 diabetes.
Evolocumab was associated with a 20% lower risk of fatal or nonfatal myocardial infarction than ezetimibe among more than 544 000 adults with ASCVD.
The FDA cleared Access MeMed BV, a host-response blood test that helps distinguish bacterial from viral infections in adults and children in as little as 15 minutes.
Greater Mediterranean diet adherence was associated with lower odds of adult acne, particularly among women, in a UK Biobank study of dietary patterns.
Abbott's investigational device achieved 96.3% complete left atrial appendage closure by echocardiography, with a 1.8% ischemic stroke rate at 1 year.
October FDA news included updates on long-acting olanzapine, multi-cancer blood testing, stroke rehabilitation, and heart failure monitoring.
Advertisement
Advertisement